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A new hexapeptide from the leader 
peptide of rMnSOD enters cells 
through the oestrogen receptor to 
deliver therapeutic molecules
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Maria Laura Pollio2, Maria Grazia Ruggiero2, Patrizia Bonelli1, Viviana De Luca3, 
Franca Maria Tuccillo1, Clemente Capasso3, Enrico Gori4, Marina Sanseverino5, 
Andrea Carpentieri7, Leila Birolo7, Piero Pucci7, Jean Rommelaere8 & Aldo Mancini9
A 24-amino acid leader peptide of a new human recombinant manganese superoxide dismutase can 
enter cells and carry molecules. Here, we demonstrated that six of the 24 amino acids penetrate cells 
through a particular gate represented by a specific amino acid sequence of the oestrogen receptor 
(ER). We analysed the internalization of the synthetic hexapeptide and the cytotoxic activity of the 
hexapeptide conjugated to cisplatin on a cell line panel. In most cell lines, the hexapeptide delivered 
an amount of cisplatin that was 2 to 8 times greater than that released by cisplatin when the drug 
was used alone. This increased delivery increases the therapeutic index of cisplatin and reduces side 
effects caused by a high dosage or long-term treatment times. We may consider this hexapeptide a new 
molecular carrier to deliver molecules with therapeutic activity into ER+ cells for diagnostic purposes 
and clinical or immune therapy.
Superoxide dismutases (SODs) are antioxidant enzymes that catalyse the O2– free radical dismutation of hydrogen 
peroxide (H2O2), thereby preventing the accumulation of these activated oxygen species. H2O2 can be further 
converted into H2O and molecular oxygen (O2) by catalase and glutathione peroxidase. At least 3 types of SODs 
are present in human tissues1, including cytoplasmic Cu/Zn-SOD, extracellular Cu/Zn-SOD (ecSOD)2 and mito-
chondrial manganese (Mn) SOD (MnSOD). The manganese-dependent MnSOD-2 is characteristic of aerobic 
organisms and is composed of four homologous 24-kDa subunits3. MnSOD is synthesized in the cytoplasm and 
then driven into the mitochondrial matrix via its leader sequence, consisting of 24 amino acids (aa). This peptide 
is subsequently cleaved, resulting in a mature and enzymatically active protein that plays a pivotal role within 
the cell. While MnSOD has been reported to protect cells from various types of insults and suppress apoptosis4, 
the compound may also be deleterious and impede cell proliferation under certain circumstances5,6. Thus, SODs 
appear to control multiple reactions essential to the determination of cell fate, particularly for cancer cells7,8. The 
excess production of reactive oxygen species (ROS) leads to cell damage, ageing and a large number of diseases; 
however, none of the commercially available SODs are administrable and able to enter cells. Moreover, these SODs 
are inactivated or excreted by the kidney9.
Recently, a new isoform of human MnSOD was isolated and obtained in a synthetic recombinant form and 
termed rMnSOD. This isoform is different due to its ability to enter cells, its intense antioxidant and antitumour 
activities and its easy administration by injection10–12. rMnSOD appears to be very effective at O2– scavenging both 
intra- and extracellularly and at improving pathological conditions associated with increased oxidative stress13. In 
addition, rMnSOD shows a good biodistribution in vivo, particularly in the liver14, suggesting that it is well suited 
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for correcting hepatic oxidative stress. Moreover, rMnSOD is radioprotective for healthy cells and radiosensitive 
for cancer cells15, and it displays a specific and selective cytotoxic activity against tumour cells expressing the oes-
trogen receptor (ER)16. rMnSOD also provides protection to rat kidneys treated with cyclosporine-A, allowing for 
the recovery of 80% of their glomerular filtrate17. Previously, we showed that rMnSOD enters cells by means of its 
24-aa leader peptide, which represents the rMnSOD molecular carrier18.
This feature of the 24-aa leader peptide that it can enter cells expressing the ER while bound to different mol-
ecules encouraged us to investigate this phenomenon. We crosslinked the 24-aa leader peptide with the ER and 
performed a mass spectrometric analysis. We identified the aa sequence of the leader peptide linked to the ER. 
The result of this assay was the identification of a 6-aa sequence that participates in ER binding. We concluded that 
this 6-aa sequence is a molecular carrier, allowing rMnSOD to enter cells. The present study examined how this 
hexapeptide was able to enter cells expressing ER and deliver into the cells the material bound to it.
Results
Identification of the rMnSOD peptide involved in the interaction with ER. Identification of the 
minimal rMnSOD peptide recognized by the ER was pursued by chemical crosslinking experiments followed by 
mass spectrometric analyses (details in the supplementary document, Mass Spectrometry Data). N-ε -maleimi-
docaproyl- oxysulfosuccinimide ester (Sulfo-EMCS), a hetero-bifunctional reagent, was selected as a crosslinker 
to take advantage of the Cys residue occurring within the 24-aa rMnSOD leader peptide. This reagent can form 
a covalent bond between Cys and Lys residues juxtaposed at an appropriate distance. The 24-residue peptide was 
then incubated with the ER protein, and the crosslinking reaction was performed in parallel with a control exper-
iment where the reagent was omitted. Following chemical modification, both the sample and control were enzy-
matically doubly digested with V8 protease and trypsin, and the resulting peptide mixture was directly analysed 
by mass spectrometry matrix-assisted laser desorption/ionization (MALDI-TOF). The mass signals recorded 
in the spectrum were assigned to the corresponding peptides within the anticipated ER sequence on the basis 
of their mass value and the proteases specificity. The mass mapping profiles of both the crosslinked sample and 
the untreated ER protein were compared. The greatest differences in the two profiles were clearly identified in 
the 450–470 region of the ER sequence; the mass signals mapping to this region could only be detected in the 
untreated ER protein, whereas they were absent in the crosslinked sample. Moreover, the chemically modified 
ER mass profile showed the occurrence of two signals at m/z 3300.7 Da and 31714.4 Da that were absent in the 
control spectra. These signals were respectively interpreted as arising from the rMnSOD hexapeptide AVCGTG 
covalently linked to fragments 450–471 and 450–470 of the ER protein SIILLNSGVYTFLSSTLKSLEE through 
the Sulfo-EMCS reagent. These results demonstrated that the small hexapeptide AVCGTG from the rMnSOD, 
similarly to the 24-residue fragment described above, could be recognized by the ER protein. This suggests that 
the hexapeptide plays the same biological role as the larger 24 aa peptide.
Synthesis of a hexapeptide (AVCGTG) and a scrambled hexapeptide (GAVCGT) conjugated to 
fluorescein. Fluorescein 6-residue peptides were synthesized by Fmoc-solid phase peptide synthesis (SPPS) 
conditions using 9-fluorenylmethoxycarbonyl (Fmoc)-chemistry. The products were released from the solid sup-
port and freed from protecting groups by acidic cleavage, precipitated with ether, filtered, re- suspended in water 
and lyophilized. Purification of the crude products by reversed-phase high- performance liquid chromatography 
(RP-HPLC) gave the desired products with 90–95% purity and the correct molecular weight (MW), as confirmed 
by mass spectrometry (MALDI-TOF).
Synthesis of the hexapeptide (AVCGTG) conjugated to cisplatin. A platinum (Pt) (II)-chelating 
6-residue peptide was synthesized by solid phase synthesis using Fmoc-chemistry. The chelant moiety and the 
coordination of Pt (II) through PtCl2 were performed according to the literature19. The product was released from 
a solid support and freed from protecting groups by acidic cleavage; it was then precipitated with ether, filtered, 
re- suspended in water and lyophilized. Purification of the crude product by RP-HPLC gave the desired product 
with 90–95% purity and the correct MW as confirmed by mass spectrometry (MALDI-TOF).
Uptake of Pt exerted by the hexapeptide conjugated to cisplatin assessed by atomic absorb-
ance spectrophotometric analysis. The presence of Pt in cancer cells following the treatment of target 
cells (approximately 4.5 × 105) with cisplatin (CisPt) or leader hexapeptide conjugated with cisplatin (LP-CC6) 
or rMnSOD 24 leader peptide conjugated with cisplatin (LP-CC24) was evaluated by atomic absorbance spec-
trophotometry. All cell lines were incubated with 11.1 μ g of Pt (92 μ M) in all treatments (CisPt and LP-CC treat-
ments). The results presented in Table 1 show the uptake of CisPt for the different treatments in cultured cell lines, 
demonstrating how the hexapeptide enters cells and that the peptide LP-CC6 delivered ~2 to 8 times more CisPt 
into the cells than CisPt alone. The significance of the differences between treatments found in this study was 
summarized according to the following parameter: the uptake of CisPt is expressed as the ratio (i.e., percentage) 
between the level of Pt in pellets compared with the supernatant. For each treatment and cell line, the statistical 
analysis was based on three independent replicates20. Based on the data in this table, we can conclude that LP-CC6 
showed a significantly greater uptake than all other treatments in A2780 (5.91), MCF-7 (4.30), A375 (15.50), 
DU145 (46.97) and HuH-7 (38.11) cells; however, in PaTu-8902 cells, LP- CC24 demonstrated a greater uptake. 
The presence of Pt was also evaluated in ER– MDA-MB-231 cell line. LPCC-6 showed a significantly lower uptake 
(Mean = 0.41; Var = 6.05 E-06; P- value = 1.0).
Cytotoxicity assay. Synthetic LP-CC6, LP-CC24 and CisPt alone were added to the culture medium at a 
final concentration of 1 μ M. Treated tumour cells were analysed for cell lysis by measuring Lactate Dehydrogenase 
(LDH) release. LDH release into the culture supernatant was expressed as a percent of total LDH (i.e., from cell 
lysis induced by detergent treatment). Approximately 3% LDH was found in the medium of untreated cultures.
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Table 2 shows the cytotoxic activity exerted by LP-CC6 and illustrates the mean level estimates of LDH based 
on the subsequent triplicate treatments of cell lines.
LP-CC6 exhibited significantly higher activity, except in PaTu-8902 cells, with a noticeable peak in ovarian 
(85.0%), breast (73.0%) and hepatocellular carcinoma (69.0%) cells.
For each cell line, the table reports the estimate of the mean (sample mean), the unbiased estimate of the pop-
ulation variance (sum of squares divided by sample size minus 1), and the p-values to test the null (one-sided) 
hypothesis that the mean level of LDH for the treatment in a row is less than or equal to the mean level of LDH for 
the treatment in the column against the alternative that the former is greater than the latter. The estimates of the 
population variance revealed clear evidence of heteroscedasticity; the p-values were computed using the one-sided 
Welch’s test for the difference between means based on independent standard samples with unequal variances20. 
The approximate degree of freedom was rounded to the next lowest integer.
Confocal analysis. Internalization of the hexapeptide in the cytoplasm of MCF-7, PaTu-8902, DU145, 
A375, A2780, HuH-7 and MCF-10A cells was demonstrated using confocal microscopy. Incubation with 92 μ M 
hexapeptide-FITC for 3 hours revealed diffuse green fluorescence of the peptide, enhanced by the use of the anti-
body II Alexa 488A, by the indirect immunofluorescence method. Movement of the confocal image plane inside 
the cells demonstrated that the detected fluorescence is located in the cells. The diffuse green fluorescence of the 
peptide was mainly detectable in the inner part of the cytoplasm of all types of cancer cell lines used and also in 
the nuclei of A375 and HuH-7 cells and slightly in the nuclei of PaTu cells (Fig. 1a). Incubation with 92 μ M scram-
bled hexapeptide-FITC for 3 hours revealed peripheral green fluorescence of the peptide demonstrating that the 
detected fluorescence is located outside the cytoplasmic membrane of MCF-7 and MCF-10A cell lines (Fig. 1b).
Clonogenic assay. The clonogenic test using normal MCF-10A cells in the presence of CisPt alone exhibited 
a cell surviving fraction of 63% at the maximal dose of 1.0 μ M. When the MCF-10A cells were treated with 1.0 μ M 
LP-CC6, the cell surviving fraction was 70% (Fig. 2). In tumour cells (i.e., MCF-7, A2780, PaTu-8902, HuH-7, 
DU145 and A375), 1 μ M LP-CC6 resulted in a cell surviving fraction ranging from 0% (MCF-7, A2780) to a 
maximum of 58% (A375); with regard to LP-CC24, the cell surviving fraction ranged from 7% (HuH-7) to 71.8% 
(A375), while the surviving factor of tumour cells in the presence of CisPt alone at the same concentration was 
almost always approximately 60% (Fig. 2).
CELL LINE TREATMENTS
Uptake Estimates P-values (***)
Mean (*) Var (**) LP-CC6 LP-CC24 CisPt
DU145
LP-CC6 46.97 8.00E-02 0.00 – 0.00
LP-CC24 13.84 4.72E-06 – 1.00 0.00
CisPt 0.91 8.52E-08 1.00 1.00 –
A2780
LP-CC6 5.91 1.19E-04 – 0.00 0.00
LP-CC24 0.65 5.22E-05 1.00 – 1.00
CisPt 0.75 5.35E-06 1.00 0.00 –
MCF-7
LP-CC6 4.30 4.13E-05 – 0.00 0.00
LP-CC24 2.60 5.49E-06 1.00 0.00 –
CisPt 0.41 6.05E-06 1.00 – 1.00
A375
LP-CC6 15.50 8.89E-05 – 0.00 0.00
LP-CC24 4.45 1.15E-03 1.00 – 0.00
CisPt 1.81 4.30E-08 1.00 1.00 –
HuH-7
LP-CC6 38.11 7.29E-06 0.00 – 0.00
LP-CC24 5.26 2.15E-06 – 1.00 0.00
CisPt 1.29 1.86E-06 1.00 1.00 –
PaTu 8902
LP-CC6 2.83 6.82E-07 – 1.00 0.00
LP-CC24 17.00 1.08E-05 0.00 – 0.00
CisPt 2.45 1.13E-08 1.00 1.00 –
MCF-10A
LP-CC6 4.29 8.48E-06 – 0.98 0.00
LP-CC24 4.34 2.21E-04 0.02 – 0.00
CisPt 1.69 6.95E-06 1.00 1.00 –
Table 1.  Uptake of cisplatin for the different treatments in cultured cell lines. In Table 1, LP-CC6 showed 
significantly greater uptake than all other treatments in A2780 (5.91), MCF-7 (4.30), A375 (15.50), DU145 
(46.97) and HuH-7 (38.11) cells; in PaTu-8902 cells, LP-CC24 demonstrated a greater uptake. Uptake of CisPt 
for the different treatments in cultured cell lines, showing how the hexapeptide enters cells. The data were 
obtained from 3 independent observations (the bars indicate the s.d.). The mean level estimates of the uptake of 
CisPt in cell lines treated with LP-CC6, LP-CC24 and CisPt; (N = 3). *Sample mean and **unbiased estimate of 
the population variance. ***based on Welch’s test20 for the null hypothesis that the mean level of uptake for the 
treatment in the row is less than or equal to the mean level of uptake for the treatment in the column, against the 
alternative that the former is greater than the latter.
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Real-time PCR analysis. The effects of LP-CC6, LP-CC24 and CisPt on tumour cells were investigated by 
real-time PCR (qPCR) by evaluating the expression of the TP53 gene that encodes a tumour suppressor protein, 
the pro-apoptotic BAX gene and the BCL2 gene, which encodes an integral outer mitochondrial membrane pro-
tein that blocks the apoptotic death of some cells, such as lymphocytes.
To verify the effect of treatment with LP-CC6, LP-CC24 and free CisPt, we analysed changes in the expression 
of the transcripts for TP53, BAX, and BCL2 by real-time PCR. Figure 3 shows the real- time PCR output from 
cell lines treated for 3 hours with LP-CC6, LP-CC24 and CisPt alone at the same molar concentration containing 
11.1 μ g of the drug. We observed increased mRNA levels of TP53 and BAX after 3 hours of treatment with LP-CC6. 
The expression of these genes was lower with LP-CC24 in all cell lines except in the melanoma cell line (A375) 
and in pancreatic carcinoma (PaTu-8902). In these cells, all three drugs exerted little effect on the expression of 
the transcripts examined. Also evident is a downregulation of the BCL2 transcript, which was well represented in 
almost all control cell lines, after treatment with LP-CC6 and LP-CC24, confirming the results obtained with the 
LDH and clonogenic assays (Fig. 2).
The expression of ER gene was evaluated by a qPCR experiment in all the cell lines examined. A high level of 
ER was observed in MCF-7 and a moderate and/or low expression in the other cell lines (Fig. 4).
Discussion
We previously demonstrated the cytotoxic activity of rMnSOD16. We also demonstrated that the 24- aa leader 
peptide alone plays a role in rMnSOD’s ability to enter tumour cells expressing the ER and deliver either rMnSOD 
or other molecules bonded to it18.
CELL LINE TREATMENTS
LDH Estimates P-values (***)
Mean 
(*) Var (**) LP LP-CC6 LP-CC24 CisPt
DU145
LP 18.2 0.367 1.000 1.000 – 1.000
LP-CC6 54.2 0.108 0.000 – 0.000 0.000
LP-CC24 36.0 0.369 – 1.000 0.000 0.003
CisPt 32.0 0.056 0.997 1.000 0.000 –
A2780
LP 4.0 0.095 – 1.000 1.000 1.000
LP-CC6 85.0 0.067 0.000 – 0.000 0.000
LP-CC24 54.0 0.032 0.000 1.000 – 0.000
CisPt 34.0 0.805 0.000 1.000 1.000 –
MCF-7
LP 22.0 0.036 – 1.000 1.000 0.990
LP-CC6 73.0 0.042 0.000 0.002 – 0.000
LP-CC24 68.0 0.334 0.000 – 0.998 0.000
CisPt 25.0 0.771 0.010 1.000 1.000 –
A375
LP 4.5 0.032 – 1.000 1.000 1.000
LP-CC6 38.0 0.411 0.000 – 0.002 0.004
LP-CC24 33.6 0.005 0.000 0.998 – 0.972
CisPt 35.0 0.543 0.000 0.996 0.028 –
HuH-7
LP 2.0 0.705 – 1.000 0.999 1.000
LP-CC6 69.0 0.060 0.000 – 0.000 0.000
LP-CC24 32.0 0.532 0.000 1.000 0.000 –
CisPt 10.0 0.155 0.001 1.000 – 1.000
PaTu- 8902
LP 6.5 0.008 – 1.000 1.000 1.000
LP-CC6 34.0 0.512 0.000 – 1.000 1.000
LP-CC24 46.0 0.478 0.000 0.000 – 0.996
CisPt 49.0 0.538 0.000 0.000 0.004 –
MCF-10A
LP 22.0 0.402 – 0.992 0.999 1.000
LP-CC6 24.0 0.307 0.008 – 0.995 1.000
LP-CC24 26.0 0.245 0.001 0.005 – 0.999
CisPt 30.0 0.219 0.000 0.000 0.001 –
Table 2.  Cytotoxicity in cell culture lines induced by different treatments. Table 2 shows the cytotoxic 
activity exerted by synthetic LP-CC6, LP-CC24 and CisPt alone and illustrates the mean level estimates of 
LDH based on the following triplicate treatments of cell lines. The hexapeptide showed more significant 
activity, except in PaTu-8902 cells, with a noticeable peak in ovarian (85.0%), breast (73.0%) and hepatocellular 
carcinoma cells (69.0%). The data were obtained from 3 independent observations (the bars indicate the s.d.). 
The mean level estimates of LDH (cytotoxic effect) in the cell lines treated with LP, LP-CC6, LP-CC24 and 
CisPt;( N = 3). *Sample mean and **unbiased estimate of the population variance. ***based on Welch’s test for 
the null hypothesis that the mean level of uptake for the treatment in the row is less or equal to the mean level of 
uptake for the treatment in the column, against the alternative that the former is greater than the latter.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:18691 | DOI: 10.1038/srep18691
Figure 1. Representative confocal internal plane images of cell lines. (a) confocal images of the 
internalization of the hexapeptide in the cytoplasm. In the first column respectively PaTu-8902, A2780, MCF-7, 
HuH-7 and in the second column the control of each adjacent cell line; in the third column respectively A375, 
DU145, MCF-10A and in the fourth column the control of each adjacent cell line. Note the green fluorescence 
dispersed in the cytoplasm. No labelling of the controls was observed. This figure is a merged image of green 
and blue fluorescence images (exc. 488 nm Argon Laser/em. BP500–550 filter). Scale bar = 14 μ m for all images 
except for A375 and its control = 25 μ m. (b) confocal images of the internalization of the scrambled hexapeptide 
in the cytoplasm of MCF-7 and MCF-10A cell lines. Scrambled does not enter both cells. It is detectable outside 
the cell membrane. Controls are not shown.
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Figure 2. Clonogenic assay. Figure 2 shows the cell surviving fraction observed after drug treatment with LP-CC6 
ranging from 0% (MCF-7, A2780 cell lines) to 58% (A375 cell line) and, for LP-CC24, from 7% (HuH-7) to 71.8% 
(A375) while the surviving fraction of tumour cells in the presence of CisPt alone at the same concentration was 
approximately 60%. The plating efficiency and the surviving fraction for each cell line after each treatment were 
calculated according to the method proposed by Franken et al.35 and averaged approximately 80% for all cell lines. 
Survival was calculated compared with non-treated samples using an average of three determinations of the same 
dose rate of cells (± SE). The average values with a standard deviation were determined from three independent 
experiments using different LP-CC6, LP-CC24 and CisPt preparations.
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We reacted the synthetic 24-aa leader peptide of rMnSOD with the ER to identify which amino acids were 
participating in the bond. Surprisingly, we found that only six of the 24 amino acids were involved in the reaction 
with a specific ER sequence (i.e., SIILLNSGVYTFLSSTLKSLEE). These amino acids represent the gate through 
Figure 3. Real-time RT-PCR analysis. Figure 3 shows analysis of mRNA levels of TP53, BAX, BCL2 in all cells 
treated with LP-CC6, LP-CC24 and CisPt alone by Real-time RT-PCR. We observed increased mRNA levels of 
TP53 and BAX after 3 hours of treatment with LP-CC6. The expression of these genes was lower in the presence 
of LP-CC24 in all cell lines except for the melanoma (A375) and pancreatic carcinoma (PaTu- 8902) cell lines. In 
these cells, all three drugs exhibited little effect on the expression of the transcripts examined. Also evident is a 
downregulation of the transcript for BCL2, well represented in almost all control cell lines, after treatment with 
LP-CC6 and LP-CC24. Each sample was normalized to human GAPDH. The bars indicate the mean values of 
three independent experiments (the bars indicate the s.d.; **p-value < 0.005; *p-value < 0.05; Student’s t-test).
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which the hexapeptide with the whole rMnSOD can enter the cells. This knowledge allows us to assign the role of 
molecular carrier to this hexapeptide and propose its therapeutic use for cells expressing the ER sequence.
The valuable properties of this molecular carrier include its ease of handling, reduced antigenicity, low cost, and 
relative ease of production. These characteristics may provide an opportunity to formulate new drugs with specific 
and selective effects for use in therapy. In fact, molecules showing therapeutic or diagnostic activities (such as radi-
oactive molecules for imaging analysis) could be conjugated to this hexapeptide and injected. In this way, targeted 
treatment could be delivered inside diseased ER+ cells. The correct MW was confirmed by mass spectrometric 
(MALDI-TOF) analysis. In all performed experiments, no toxic alterations were observed in cells displaying inter-
nalization of the hexapeptide alone. Confocal microscopic analysis of all focal planes revealed that the FITC-peptide 
penetrated cancer cells by entering the cytoplasm, where it was detected in all treated cells. These results are in 
agreement with previous immunocytochemical detection reports using a polyclonal antibody directed against the 
24-aa leader sequence of rMnSOD21. To verify the capacity of the hexapeptide to deliver molecules into tumour 
cells, a synthetic construct, LP-CC6, was prepared. Quantitative CisPt determination demonstrated that LP-CC6 
delivered high amounts of platinum into the cells, more than that released into cells when CisPt was used alone.
The atomic absorbance spectrophotometric analysis required, in the experiments with LP-CC6, a high concen-
tration of CisPt conjugated to the hexapeptide (i.e., 11.1 μ g, corresponding to 92 μ M). However, the toxic effect of 
LP-CC6 is already high at a concentration of 1 μ M for 48 hr (i.e., LDH release, clonogenic assay). This is significantly 
lower than the concentration required to CisPt alone to induce apoptosis in MCF-7 cells (i.e., 80–160 μ M for 24 h)22. 
It is important to note that, despite a positive uptake of LP-CC6 by normal cells, apoptosis was undetectable, as 
confirmed by LDH release (Table 2) and BAX, TP53, and BCL2 gene expression (Fig. 3).
The reason for differences in uptake may be related to the fact that the low amount of CisPt contained in LP-CC6 
may not be sufficient to reach the toxic threshold, given that, in normal cells, there are detectable levels of antiox-
idant enzymes (i.e., MnSOD and catalase). In normal cells, these enzymes can neutralize the cytotoxic effect of 
CisPt-derived free radicals. In contrast, the amount of CisPt taken up by cancer cells is highly toxic because these 
enzymes, particularly catalase, are poorly expressed in cancer cells12.
The cytotoxic activity exerted by the hexapeptide conjugated to CisPt was significantly high, with a particular 
peak of activity in ovarian, breast, prostatic and hepatocellular carcinoma cells. Less cytotoxicity was exerted on 
pancreatic cells by LP-CC6, but it was still sufficient to kill cancer cells. We are unable to explain the reasons for the 
variations in cytotoxicity across cell lines; however, some hypotheses can be formulated regarding this effect. The 
most likely explanation is that there is a different level of expression of oestrogen receptors in these cells (Fig. 4). 
The analysis of expression of ER gene by a qPCR experiment confirmed that the increased cytotoxicity is related 
to the different expression of ER in cells. Several authors investigated the correlation between cisplatin cytotoxicity 
and ER presence. Some described that the treatment of human cancer cells that have steroid hormone receptors 
with the appropriate hormone, oestrogen and/or progesterone, significantly increased the potency of cisplatin by 
causing the overexpression of HMG1. These endogenous HMG1 proteins were already involved in complexes with 
chromatin and transcription factors. They, expressed as a scaffold to facilitate ER- or PR-mediated transcription, 
may be more readily available to bind to cisplatin-DNA intra-strand crosslinks23. Other findings suggested that 
HMG1 induction as an enhancer of platinum sensitivity was mediated through interaction between oestrogen 
and ER-α in patients with prostate cancer24. Another evidence of the correlation between cisplatin cytotoxicity 
and ER presence was that several oestrogen-tethered platinum (IV) complexes (BEP) were prepared. They were 
inspired by the observation that oestrogen receptor-positive cells exposed to the hormone are sensitized to cispla-
tin25. Moreover, in MCF7 cells in which oestrogen receptor is activated, DNA damage inhibited checkpoint cell 
cycle, which resulted in less effective DNA repair. In the cancer cells, where oestrogen receptor is inhibited, there 
was a better DNA repair and improved cell survival, which decreased the cytotoxic action of cisplatin26. BRCA1 
has been proved to interact physically with ER-α and inhibit its transcriptional activity. BRCA1-defective cells 
displayed significantly higher sensitivity to cisplatin supporting the idea that cisplatin-induced DNA damage is 
strongly associated with the inactivation of BRCA127.
Figure 4. ER expression analysis by Real-time RT-PCR. Figure 4 shows analysis of mRNA levels of ESR in all 
cells examined by Real-time RT-PCR. We observed higher level of ESR in MCF-7 and a moderate and/or low 
expression in the other cell lines. Each sample was normalized to human GAPDH. The bars indicate the mean 
values of three independent experiments (the bars indicate the s.d.; **p-value < 0.005; *p-value < 0.05; Student’s 
t-test).
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We are preparing a specific antibody against the aa sequence of the ER to verify the correlation between ER 
and LP. This sequence could crosslink with the leader peptide when entering the cells. CisPt is a drug widely used 
in chemotherapy that causes damage to DNA by alkylation and determination of crosslinks. The exact processes 
responsible for CisPt-induced cell death and the processes involved in regulating CisPt sensitivity are still being 
studied22. One of the major problems caused in the clinic by use of CisPt is the appearance of severe dose-dependent 
side effects. Because of these side effects, many tumours become resistant due to high dosage or long- term treat-
ment. Moreover, it is important to highlight that, to achieve significant toxicity, as in the case of MCF-7 cells (but 
also equally significant in other tumour cells) when using CisPt alone, it was necessary to use at least a 25 μ M 
concentration, corresponding to 730 ng of CisPt. However, when using LP-CC6, to produce the same cytotoxicity, 
only a 1.0 μ M concentration was needed, corresponding to only 30 ng of CisPt.
We chose to use real-time PCR to evaluate the expression of three genes (TP53, BAX, BCL2) that are involved 
in apoptosis. Our data18 showed that both the 24-aa leader peptide linked to CisPt, as well as the hexapeptide 
linked to CisPt, at the low concentrations used, activate apoptotic genes (i.e., BAX and TP53) while inhibiting the 
antiapoptotic gene BCL2, in line with reports in the literature28–34.
It is hence easy to note that the delivery of a small but critical amount of CisPt carried by LP-CC6 and released 
directly into tumour cells resulted in an increased therapeutic index of CisPt, which produced more marked cyto-
toxicity in tumour cells and increased tumour cell death. On the other hand, it is well known that the therapeutic 
effect of drugs for tumour cells is related to the lesion being exposed to a critical (and not necessarily plasmatic) 
concentration of the molecule as well as to a high retention of the drug or its metabolites35–38. These are exactly the 
conditions generated by the LP-CC6 injection, which led to an increased therapeutic index of CisPt.
The data we obtained were significant, and the main results from the cytotoxicity data can be summarized as 
follows: LP-CC6 displayed a greater cytotoxic effect (i.e., was more effective) than CisPt in all cancer cell lines with 
the exception of PaTu-8902 cells and A375 cells, in which CisPt alone or linked to peptides was most effective. 
Many authors have studied the mechanisms of cellular resistance to apoptosis induced by chemotherapy, particu-
larly in pancreatic cancer cells39. Interestingly, in normal MCF-10 cells, LP-CC6 was less toxic than usual. A key 
ability of a drug is to penetrate target cells, and the hexapeptide clearly demonstrated this skill. We found that the 
hexapeptide delivered and released 2 to 8 times more CisPt than the 24-aa leader peptide in all tumour cells except 
for PaTu-8902, MCF-10A and MDA-MB-231 cell lines. This observation demonstrates that CisPt fails to reach the 
site of tumour lesions, and this may be the case for other cytostatics as well. This observation is not of secondary 
importance; in fact, because cytostatic agents are antireplicative, mutagenic and oncogenic, they should be used in 
patients with caution in very small doses to minimize or eliminate side effects due to high toxicity. Unfortunately, 
their inability to reach and penetrate tumour lesions18 leads clinicians to use high doses of these drugs, which 
results in unpleasant side effects for the patients. Therefore, the use of the hexapeptide as a molecular carrier could 
help ameliorate the therapeutic effects by increasing the internalized dose, which would reduce the given dose and 
thereby minimize the side effects.
In conclusion, the present study provides strong evidence that the hexapeptide, when conjugated to CisPt and 
added to cells in vitro, penetrated cells through an aa sequence of the ER and delivered high amounts of CisPt. The 
aa sequence of the ER represents a gate through which the rMnSOD or any other molecule bound to a hexapeptide 
can be delivered into the cells. This targeted delivery increases the therapeutic index of CisPt, which, despite its 
low dose, was able to kill cancer cells. Finally, because the hexapeptide avoids biological barriers, quickly enters 
cells and is easy to administer, we believe that this construct is more versatile than the original 24-aa peptide and 
should, therefore, be considered as an anticancer agent. We conclude that cell penetration is an essential prerequisite 
for signal transduction therapy, therapies influencing transcription and translation, and thus, effective tumour 
therapy; additionally, it may be useful for gene therapy in the future.
Materials and Methods
Reagents. The 24-aa rMnSOD leader peptide, the new leader hexapeptide (LP; AVCGTG) and the scrambled 
hexapeptide (GAVCGT) were obtained according to described methods. The anti- 24-aa leader peptide primary 
polyclonal antibody (rabbit) was distributed by PRIMM BIOTECH (Milan, Italy). This antibody was used at a 
concentration of 1:200. CisPt was purchased from Bristol-Mayer Co. (New York, NY, USA).
Synthesis of hexapeptide (AVCGTG) and of scrambled hexapeptide (GAVCGT) conjugated to 
fluorescein. The peptides were synthesized step-wise in batch-mode on a solid support with an automatic 
synthesizer, Syro (MultiSynTech), using Fmoc/tBu chemistry40 starting from the C- terminal residue pre-loaded 
on PS-PHB resin with an average of 0.57 mmol/g substitution (Rapp Polymere). Synthesis on a 30 micromol scale 
proceeded through standard cycles of Fmoc de- protection [piperidine: DMF, 0.2:1(v/v)] and Fmoc- amino acid 
coupling [Resin: Fmoc-amino acid: HBTU: DIEA, 1:4:4:8]41.
Amino acid derivatives for hexapeptide (AVCGTG): Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc- Cys (Trt)-OH, 
Fmoc-Gly-OH, Fmoc-Thr (tBu)-OH.
Amino acid derivatives for scrambled hexapeptide (GAVCGT): Fmoc-Ala-OH, Fmoc-Cys (Trt)-OH, 
Fmoc-Gly-OH, Fmoc-Thr (tBu)-OH, Fmoc-Val-OH. Fluorescein was coupled to a peptidil-resin using 
5(6)-FAM:HBTU:DIEA in a 4:4:8 ratio.
Cleavage. Side chain de-protection with a concomitant cleavage of the peptides from a solid support were 
obtained by suspending the protected peptide resin in a mixture of TFA:water [95:5 (v/v)] for three hours. The 
resin was removed by filtration under reduced pressure. Precipitation was achieved by collecting the filtrate on 
a bed of cold ether. After several ether washes, the crude compounds were suspended in water (0.1% TFA, v/v) 
and lyophilized.
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Analysis. Purity was assessed by analytical RP-HPLC (Shimadzu) using a Vydac C18 column (4.6 × 150 mm) 
with eluent A (0.1%TFA in water) and eluent B (0.1%TFA in acetonitrile) over a gradient spanning 5% B to 65% 
B over the course of 20 min at a flow rate of 1 mL/min (R.t.) for 16.5 min. Identity was assessed by mass spectrom-
etry performed on a MALDI-TOF spectrometer (Applied BioSystem) [MH+ = 866].
Synthesis of the hexapeptide (AVCGTG) conjugated to cisplatin. The peptide was synthesized 
step-wise in batch-mode on a solid support with an automatic synthesizer, Syro (MultiSynTech), using Fmoc/tBu 
chemistry40 starting from the C-terminal residue pre-loaded on PS-PHB resin with an average of 0.57 mmol/g 
substitution (Rapp Polymere). Synthesis on a 30-micromol scale proceeded through standard cycles of Fmoc 
deprotection [piperidine: DMF, 0.2:1(v/v)] and Fmoc-amino acid coupling steps [Resin: Fmoc-amino acid: 
HBTU: DIEA, 1:4:4:8]41. As a Pt binder, diamino-ethyl-glycine was used, which, by virtue of the presence of two 
free amine groups, can combine platinum (II) ions as PtCl219.
Amino acid derivatives: Fmoc-Ala-OH, Fmoc-Val-OH, Fmoc-Cys (Trt)-OH, Fmoc-Gly-OH, Fmoc-Thr 
(tBu)-OH.
Binder: N-Fmoc [N′-Fmoc-(2′ aminoethyl)] glycine.
Cleavage. Side chain de-protection with concomitant cleavage of the peptide from a solid support was 
achieved by suspending the protected peptide-resin in a mixture TFA and water [95:5 (v/v)] for three hours. The 
resin was removed by filtration under reduced pressure. Precipitation was achieved by collecting the filtrate on a 
bed of cold ether. After several ether washes, the crude compound was suspended in water (0.1% TFA, v/v) and 
lyophilized.
Analysis. Purity was assessed by analytical RP-HPLC (Shimadzu) using a Vydac C18 column (4.6 × 150 mm) 
with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in acetonitrile) over a gradient spanning 5% B to 65% 
B over the course of 20 min at a flow rate of 1 mL/min. (R.t.) for 16.5 min. Identity was assessed by mass spectrom-
etry performed on a MALDI-TOF spectrometer (Applied BioSystem) [MH+ = 870].
Purification. RP-HPLC purification was performed on a Vydac C18 column (22 × 250 mm) with eluent A 
(0.1% TFA in water) and eluent B (0.1% TFA in acetonitrile) at a gradient from 5% B to 65% B over the course of 
40 min at a flow rate of 20 mL/min).
Cell lines. The cell lines used in this study included MCF-7 human mammary cancer cells (ATCC, HTB-22), 
A2780 human ovarian cancer cells (Sigma, 93112519), PaTu-8902 pancreatic adenocarcinoma cells (DSMZ, n° 
ACC179), HuH-7 human hepatocarcinoma cells (JCRB Cell Bank JCRB043, National Institute of Biomedical 
Innovation), MCF-10A normal breast cell (ATCC, CRL-10317), DU145 prostatic adenocarcinoma (ATCC, HTB-
81), A375 human melanoma cells (ATCC, CRL 1619) and MDA-MB-231 human mammary cancer cells (ATCC, 
HTB-26). All cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% foetal bovine 
serum. The cells were incubated at 37 °C in a humidified atmosphere with 5% CO2 .
Uptake of cisplatin into tumour cells evaluated by atomic absorbance spectrophotometric 
analysis. Samples of each target cell used in the present study were treated for 2 hours in the presence of 
92 μ M CisPt, 92 μ M LP-CC24 and 92 μ M LP-CC6 cultured in DMEM with 10% FCS (Gibco, Life Technologies 
Italia). The controls were obtained by maintaining the same cells under the same culture conditions but with 
the presence of 92 μ M of the 24-aa leader peptide alone or 92 μ M of hexapeptide, both in the absence of CisPt. 
Given the sensitivity of this method, the amount of the sample must also be considered. It must be highlighted 
that for the determination of platinum using a spectrofluorimeter, it was necessary to use a high concentration of 
platinum conjugated to the hexapeptide, i.e., 11.1 μ g or a 92 μ M concentration in molar terms. Determinations 
are performed in triplicate. Target cells were collected, washed twice with phosphate buffer saline 1X (PBS) and 
treated with 50 μ L of 35% HNO3 for 16 hours. After a 3-hour incubation, Pt content in the growth medium and 
the cell pellet was determined by graphite furnace atomic absorption spectrophotometry (Analyst 800, Perkin–
Elmer, Norwalk, CT, USA) using the following parameters: pre-treatment temperature, 1,300 °C; atomization 
temperature, 2,200 °C; and matrix modifer, 0.015 mg of Pd (Palladium) and 0.01 mg of Mg(NO3)2. Measurements 
were performed using a graphite furnace equipped with a Zeeman-effect background correction system. A pyro-
lytic graphite-coated THGA tube (Perkin–Elmer) with an integrated Lvov-type platform was used for metal 
determination. A Pt standard in 2.5% HNO3 (Spectrascan) was used as a stock solution for the construction of 
the 3-point calibration curve. Each measurement was performed in triplicate.
Cytotoxicity assay. Cell lysis induced by LP-CC6 treatment was measured by the release of the lactate 
dehydrogenase (LDH) enzyme. LP-CC24, LP alone or CisPt alone were added to exponentially growing cultures 
of MCF-7, A2780, PaTu-8902, HuH-7, MCF-10A, DU145 and A375 cells at a final concentration of 1 μ M. The 
concentration of 1 μ M was chosen because we previously demonstrated that, while treating MCF-7 and other 
tumour cells with increasing concentrations of LP-CC6 (0.06 to 36.8 μ M) for 48 hours, the optimal concentration 
of LP-CC6 based on a LDH assay was between 0.5 and 1 μ M18. LDH released into the culture supernatant was 
expressed as the percent of total LDH from cell lysis induced by detergent treatment. Approximately 3% LDH 
was found in the medium of untreated cultures. LDH release into the medium supernatant was measured at the 
indicated times post-application (i.e., 48 hours) using the CytoTox 96 nonradioactive cytotoxicity assay kit from 
Promega (Promega Italia, S.r.l. Milan, Italy) according to the manufacturer’s recommendations. Experiments were 
performed in triplicate using different preparations.
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Confocal analysis. MCF-7, PaTu-8902, DU145, A375, A2780, and HuH-7 cell lines underwent direct and 
indirect immunofluorescent assays for hexapeptide detection. In order to detect the scrambled hexapeptide 
direct and indirect immunofluorescent assays were performed on MCF-7 and MCF-10A. For both methods 
of detection, all cells were incubated with 92 μ M AVCGTG-FITC for 3 hours in glass-bottom dishes (MatTek 
Corporation, Ashland, MA, USA), fixed with 4% paraformaldehyde/PBS for 15 min and rinsed twice with 1X 
PBS containing 0.1% Triton to remove traces of fixative. For indirect immunofluorescence, after washes and per-
meabilization with 0.4% Triton X-100/PBS for 15 min, blocking was performed with normal horse serum NGS 
(Vector, USA), 3% BSA, and 0.1% Triton X-100/PBS. Cells were incubated with the anti-24-aa leader peptide 
primary polyclonal antibody (rabbit) overnight at 4 °C. After three washes with 1X PBS, cells were incubated 
with CF 488 A (Biotium, CA) for 2 hours in the dark at room temperature. Untreated cell samples (i.e., without 
AVCGTG-FITC) were used for the background control. For both immunofluorescence methods, nuclei were 
stained with 4′ , 6-diamidino-2-phenylindole (DAPI; 10 μ g/mL). The slides were stored in the dark at 4 °C and 
then observed on a confocal microscope (LSM 510 META, Zeiss).
Clonogenic tests on normal and tumour cells following LP-CC6, LP-CC24, and CisPt treat-
ment. Confluent 75-cm2 flasks of tumour (MCF-7, A2780, HuH-7, DU145, A375, PaTu-8902) or normal 
(MCF-10A) cells were trypsinized, counted with a haemocytometer and diluted with incomplete media to obtain 
100 cells ⁄ mL. Two millilitres of cell suspension was plated in each well (BD Falcon six-well tissue culture plate) 
to obtain 200 cells per well. Normal and tumour cells were treated in the presence of LP-CC6, LP-CC24 and CisPt 
at final concentrations of l μ M. Experiments were performed in triplicate. Colonies were stained with crystal 
violet after 14 days, and those colonies containing at least 30 cells were counted as surviving colonies. The plating 
efficiency and the survival fraction for each cell line after each treatment were calculated according to the method 
proposed by Franken et al.42 and averaged approximately 80% for all cell lines. Survival was calculated in com-
parison with non-treated samples, using an average of three determinations of the same dose rate of cells (± SE). 
Average values with a standard deviation were determined from three independent experiments using different 
LP-CC6, LP-CC24 and CisPt preparations.
Real-time PCR assay in cells treated with LP-CC6, LP-CC24 and CisPt. Target cells: three inde-
pendent samples of each of the target cells used in the present study (MCF-7, MCF-10A, A2780, A375, HuH-7, 
DU145 and PaTu-8902) were treated for 3 hours with 92 μ M of CisPt or 92 μ M LP-CC6 (containing an equivalent 
CisPt concentration) cultured in DMEM with 10% FCS (Gibco). The controls were obtained by maintaining the 
same cells in identical culture conditions but in the presence of 92 μ M of peptide alone in the absence of CisPt. 
RNA extraction: the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) was used to extract total RNA from target 
cells. Contaminating genomic DNA was removed using gDNA Eliminator spin columns (Qiagen). The purity and 
integrity of the isolated RNA were determined using a spectrophotometer, denaturing agarose gel electrophoresis 
and an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The RNA integrity values of the isolated RNA 
were nearly 10. Total RNA, isolated from cells as described above, was used for cDNA synthesis. RT-PCR analyses 
of the tumour protein p53 gene (TP53), Bcl-2-associated X protein gene (BAX) and B-cell CLL/lymphoma 2 gene 
(BCL2) were performed with ABI PRISM 7000 Sequence Detection System instruments and software (Applied 
Biosystems, Foster City, CA, USA) using the Power SYBR Green PCR Master Mix (Applied Biosystems) with 
the thermocycler conditions recommended by the manufacturer. RT-PCR analyses of oestrogen receptor gene 
(ESR) were also performed. All reactions were performed in a total volume of 25 μ L containing 50 ng of cDNA 
and 2.5 μ L of 10X QuantiTect Primer (Qiagen). Reactions were performed in triplicate on three independent sets 
of RNA. The QuantiTect Primers have been bioinformatically validated to detect RNA only, provided that no 
pseudogenes with high cDNA similarity exist and the transcript is not derived from a single-exon gene. Negative 
controls (i.e., no RNA added) were processed under the same conditions as experimental samples. Human glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control to normalize target gene 
expression (Δ Ct) and to correct for experimental variation43. The relative gene expression was calculated using 
the method described by Livak and Schmittgen44 and is expressed as the fold change compared with the control.
Statistical Analysis
All data related to real-time PCR are shown as the mean ± s.d. Student’s t-test was used to determine the signifi-
cance of the observed data.
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